Tagged with GEN

Switzerland Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the Swiss government, and the reimbursement and market challenges facing Biogen in 2021 and beyond.   2020 saw a lot of…

Switzerland Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the way we look at sex and gender as a gateway to precision medicine. She explains how artificial intelligence (AI) is…

Russia The latest Russia Pharma News, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce insulin in Venezuela, the bypassing of Gilead’s Remdesivir IP, and the Russian government’s decision to delay approvals of Chinese vaccines in favor of local shots.   Russian Biocad plans to produce…

Singapore Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers in Singapore and beyond, and why Asian representation in clinical trials is of vital importance moving forward.   Technology has…

Switzerland Dr Remo Gujer gives an overview of the BMS footprint in Switzerland and Austria, the ongoing integration of legacy Celgene operations, market access challenges, clinical trials, and the importance of digitalisation.   There is so much healthcare data available today but not enough is being collected or used in an…

Switzerland Andrea Emilio Rizzoli of the Dalle Molle Institute for Artificial Intelligence, among the top 10 in the world in its field of research, outlines the focus of the Institute today, the synergies between AI and healthcare, and how pharma companies might structure their AI investments in the future.   When…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from  – and…

USA Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the USA’s largest generic industry body, how the COVID-19 pandemic has altered the discussion around generics and essential medicines, and his hopes for the Biden administration  …

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…

Switzerland Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer modelling; and how it is looking to leverage its connections to the rest of Switzerland and to Italy.   A…